New treatments outperforming placebo becoming less common

New treatments outperforming placebo becoming less common
The efficacy of new medical treatments compared with placebo has sharply declined over the last few decades, suggesting that comparative effectiveness studies are needed, according to a study published in the June issue of Health Affairs.

(HealthDay)—The efficacy of new medical treatments compared with placebo has sharply declined over the last few decades, suggesting that comparative effectiveness studies are needed, according to a study published in the June issue of Health Affairs.

Mark Olfson, M.D., M.P.H., from Columbia University in New York City, and Steven C. Marcus, Ph.D., from the University of Pennsylvania in Philadelphia, randomly selected and analyzed 315 placebo-controlled trials published in BMJ, the Journal of the American Medical Association, The Lancet, and the New England Journal of Medicine from 1966 to 2010.

The researchers found that the average effect size or average difference in efficacy fell significantly between the active treatment and placebo, from a peak odds ratio of 4.51 (1971 to 1980) to 1.36 (2001 to 2010).

"A decline in effect sizes in conventional placebo-controlled trials supports an increased emphasis on other avenues of research, including comparative studies on the safety, tolerability, and cost of treatments with established efficacy," Olfson and colleagues conclude.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Placebo often effective for treating headache in children

Jan 29, 2013

(HealthDay)—Placebo is often effective in treating children with headaches, and innovative strategies are needed to reduce the placebo response rate and prove drug effects in trials, according to two studies ...

Collagenase clostridium histolyticum OK in Peyronie's

Apr 26, 2013

(HealthDay)—For patients with Peyronie's disease, treatment with collagenase clostridium histolyticum (CCH) intralesional injections is efficacious and tolerable, according to research published online ...

Imeglimin beneficial as add-on to metformin in T2DM

Dec 14, 2012

(HealthDay)—For patients with type 2 diabetes inadequately controlled by metformin alone, addition of the new oral anti-diabetes agent imeglimin improves glycemic control with good tolerability and safety, ...

Recommended for you

Report highlights progress, challenges in health IT

16 hours ago

(HealthDay)—Progress has been made toward widespread adoption of electronic health records (EHRs), although there are still barriers to adoption of advanced use of EHRs, according to a report published ...

Training your brain to prefer healthy foods

16 hours ago

It may be possible to train the brain to prefer healthy low-calorie foods over unhealthy higher-calorie foods, according to new research by scientists at the Jean Mayer USDA Human Nutrition Research Center ...

Outdoor enthusiasts need a lightning plan

16 hours ago

(HealthDay)—Those partaking in outdoor sports and activities need to be aware of the threat posed by lightning and take appropriate safety measures, experts say.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

JRi
5 / 5 (1) Jun 15, 2013
Probably something to do with more strict guidelines, how tests need to be carried out nowadays. Laws require to inform authorities in advance when starting new tests. More difficult for pharmaceutical companies to "forget" the trials that failed to give positive outcome.
Wolf358
5 / 5 (1) Jun 15, 2013
Maybe it's all of the new improved extra-strength placebos....